Johnson & Johnson (JNJ) Non Operating Income (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Non Operating Income came in at -$294.0 million in Q1 2026, down 104.02% year-on-year from $7.3 billion in Q1 2025, and up 39.13% quarter-over-quarter from -$483.0 million in Q4 2025.

Johnson & Johnson (JNJ) Non Operating Income (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Non Operating Income across 18 years of filings, most recently posting -$294.0 million for Q1 2026.

  • Non Operating Income for Q1 2026 came in at -$294.0 million, down 104.02% year-over-year; the trailing twelve-month figure through Mar 2026 was -$406.0 million (down 108.07% YoY), and the FY2025 annual result was $7.2 billion, up 253.58% from the prior year.
  • Non Operating Income came in at -$294.0 million for Q1 2026 at Johnson & Johnson, up from -$483.0 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $7.3 billion in Q1 2025 to a low of -$6.9 billion in Q2 2023.
  • The 5-year median for Non Operating Income is -$273.0 million (2022), against an average of -$302.4 million.
  • Across the five-year window, Non Operating Income sank 6903.92% in 2023 and surged 404.53% in 2025, its largest moves.
  • Johnson & Johnson's Non Operating Income stood at -$226.0 million in 2022, then surged by 286.28% to $421.0 million in 2023, then plunged by 61.76% to $161.0 million in 2024, then plunged by 400.0% to -$483.0 million in 2025, then surged by 39.13% to -$294.0 million in 2026.
  • The last three Non Operating Income figures came in at -$294.0 million (Q1 2026), -$483.0 million (Q4 2025), and $478.0 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn 195.49 Mn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn -65.00 Mn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn -294.00 Mn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn -2.31 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn -138.00 Mn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn 75.00 Mn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn 235.00 Mn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn -861.00 Mn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn -32.00 Mn
10 Novartis Ag 108.28 Bn 107.60 Bn - -

Historic Data

Download Data
DateValue
Mar 29, 2026 -294.00 Mn
Dec 28, 2025 -483.00 Mn
Sep 28, 2025 478.00 Mn
Jun 29, 2025 -107.00 Mn
Mar 30, 2025 7.32 Bn
Dec 29, 2024 161.00 Mn
Sep 29, 2024 -1.80 Bn
Jun 30, 2024 -653.00 Mn
Mar 31, 2024 -2.40 Bn
Dec 31, 2023 421.00 Mn
Oct 1, 2023 -499.00 Mn
Jul 2, 2023 384.00 Mn
Apr 2, 2023 -6.94 Bn
Jan 1, 2023 -330.00 Mn
Oct 2, 2022 -226.00 Mn
Jul 3, 2022 -273.00 Mn
Apr 3, 2022 102.00 Mn
Oct 3, 2021 -1.85 Bn
Jul 4, 2021 488.00 Mn
Apr 4, 2021 882.00 Mn